13F Holdings
中文EN

RLAY Relay Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1812364 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY23.9%
TTM net income YoY1.3%
TTM EPS YoY12.8%
Revenue 3-yr CAGR-26.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-3,094.6%
Net margin-2,837.0%
FCF margin—
EBITDA margin-3,077.7%

Returns

ROE-41.2%
ROA-37.4%
ROIC (approx.)-41.8%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets9.2%
Debt / equity0.00x
Current ratio14.62x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$15.36M$10.01M$25.55M$1.38M$3.03M
R&D expense$261.38M$319.09M$330.02M$246.35M$172.65M
SG&A expense$56.71M$76.59M$74.95M$65.98M$57.39M
Operating income-$302.74M-$372.47M-$373.00M-$299.27M-$364.70M
Income tax$0$0$0$0$0
Net income-$276.48M-$337.71M-$341.97M-$290.51M-$363.87M
EBITDA-$299.18M-$367.00M-$367.73M-$295.14M-$360.77M
EPS (basic)-1.61-2.36-2.79-2.59-3.82
EPS (diluted)-1.61-2.36-2.79-2.59-3.82
Weighted avg. shares (diluted)———112.23M95.14M
Balance sheet
Cash & equivalents$84.02M$126.41M$146.44M$154.37M$282.70M
Receivables———$306,000$403,000
Current assets$578.28M$809.20M$770.10M$1.02B$976.24M
PP&E, net$1.73M$5.91M$10.90M$11.63M$6.54M
Intangibles——$2.30M$2.30M$2.30M
Total assets$621.33M$871.30M$843.98M$1.10B$1.01B
Current liabilities$25.58M$50.73M$30.27M$63.71M$24.32M
Total liabilities$54.27M$93.50M$91.98M$149.55M$110.64M
Shareholders' equity$567.06M$777.79M$752.00M$950.22M$897.81M
Shares outstanding173.87M167.76M127.46M121.11M108.21M
Cash flow statement
Operating cash flow-$235.46M-$249.11M-$300.32M-$229.49M-$74.41M
Capital expenditure$410,000$2.02M$4.13M$9.06M$3.47M
Free cash flow-$235.87M-$251.12M-$304.44M-$238.55M-$77.88M
Investing cash flow$192.80M-$41.08M$257.63M-$188.75M-$479.51M
Financing cash flow$1.60M$270.15M$34.75M$289.91M$388.09M
Depreciation & amortization$3.56M$5.46M$5.27M$4.13M$3.92M
Stock-based compensation$62.42M$94.14M$86.03M$56.14M$48.45M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.